Dear Editor, I am writing to draw attention to the growing concern of Metabolic Dysfunction‐Associated Fatty Liver Disease (MAFLD), a new term for an old multisystem disorder, a term that replaced NAFLD in early 2020 (1). The global prevalence of MAFLD is estimated to be around 25- 32% of the adult population (2). This makes it one of the most common chronic liver diseases worldwide.